Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * RASTETTER WILLIAM H 2. Date of Event Requiring Statement (Month/Day/Year) 10/14/2026 3. Issuer Name and Ticker or Trading Symbol Iambic Therapeutics, Inc. [IAM] (Last) (First) (Middle) C/O IAMBIC THERAPEUTICS, INC., 5627 OBERLIN DRIVE, SUITE 120 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) __X__ Other (specify below) Chairperson of the Board 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) SAN DIEGO, CA 92121 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Convertible Preferred Stock	(1)	(1)	Common Stock	76,801	(1)	I	See footnote(2)
Series B-2 Convertible Preferred Stock	(3)	(3)	Common Stock	64,001	(3)	I	See footnote(2)
Series B-3 Convertible Preferred Stock	(4)	(4)	Common Stock	36,805	(4)	I	See footnote(2)
Series B-4 Convertible Preferred Stock	(5)	(5)	Common Stock	14,972	(5)	I	See footnote(2)
Stock Option (right to buy)	(6)	04/17/2033	Common Stock	66,556	$3	D
Convertible Promissory Notes	10/16/2026	08/14/2028	Common Stock	8,341(7)	(8)	I	See footnote(2)

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
RASTETTER WILLIAM H C/O IAMBIC THERAPEUTICS, INC. 5627 OBERLIN DRIVE, SUITE 120 SAN DIEGO, CA 92121	X			Chairperson of the Board

Signatures

/s/ Sunny Chang, by power of attorney		10/14/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Each share of Series B Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
(2)	The shares are held of record by the Rastetter Family Trust dated September 2, 2010, for which Dr. Rastetter serves as a trustee.
(3)	Each share of Series B-2 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
(4)	Each share of Series B-3 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
(5)	Each share of Series B-4 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
(6)	Twenty-five percent of the shares subject to the option vested on March 9, 2024 and 1/48th of the shares vest monthly thereafter.
(7)	The amount of shares reported assumes the Issuer's initial public offering price per share (the "IPO Price") to be $16.00 per share.
(8)	The conversion price is equal to the lower of (i) 85% of the IPO Price (reflecting a 15% discount) and (ii) the price per share implied by a $900.0 million valuation cap.
Remarks: Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.